BBIO
Income statement / Annual
Last year (2025), BridgeBio Pharma Inc's total revenue was $502.08 M,
an increase of 126.26% from the previous year.
In 2025, BridgeBio Pharma Inc's net income was -$729.31 M.
See BridgeBio Pharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$502.08 M |
$221.90 M |
$9.30 M |
$77.65 M |
$69.72 M |
$8.25 M |
$40.56 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$28.27 M
|
$3.88 M
|
$2.45 M
|
$3.43 M
|
$3.11 M
|
$0.00
|
$2.50 M
|
$0.00
|
$260.00 K
|
| Gross Profit |
$473.81 M
|
$218.02 M
|
$6.86 M
|
$74.21 M
|
$66.60 M
|
$8.25 M
|
$38.06 M
|
$0.00
|
-$260.00 K
|
| Gross Profit Ratio |
0.94
|
0.98
|
0.74
|
0.96
|
0.96
|
1
|
0.94
|
0
|
0
|
| Research and Development Expenses |
$477.54 M
|
$506.46 M
|
$455.71 M
|
$399.46 M
|
$451.02 M
|
$337.05 M
|
$209.95 M
|
$140.07 M
|
$30.56 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$555.14 M
|
$288.93 M
|
$150.59 M
|
$143.19 M
|
$192.21 M
|
$145.68 M
|
$94.35 M
|
$43.59 M
|
$13.30 M
|
| Other Expenses |
$10.22 M
|
$15.61 M
|
$7.93 M
|
$43.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$1.04 B
|
$811.00 M
|
$614.23 M
|
$586.42 M
|
$643.23 M
|
$482.73 M
|
$304.30 M
|
$183.66 M
|
$43.86 M
|
| Cost And Expenses |
$1.07 B
|
$814.88 M
|
$616.67 M
|
$589.85 M
|
$646.35 M
|
$482.73 M
|
$306.80 M
|
$183.66 M
|
$43.86 M
|
| Interest Income |
$19.85 M
|
$17.25 M
|
$18.04 M
|
$7.54 M
|
$1.13 M
|
$4.02 M
|
$8.92 M
|
$2.00 M
|
$39.00 K
|
| Interest Expense |
$53.10 M
|
$99.29 M
|
$81.29 M
|
$80.44 M
|
$46.78 M
|
$36.66 M
|
$8.77 M
|
$2.55 M
|
$13.00 K
|
| Depreciation & Amortization |
$9.00 M
|
$6.08 M
|
$6.49 M
|
$6.77 M
|
$5.84 M
|
$1.46 M
|
$859.00 K
|
$245.00 K
|
$260.00 K
|
| EBITDA |
-$672.88 M |
-$436.83 M |
-$565.47 M |
-$397.44 M |
-$533.83 M |
-$467.38 M |
-$278.96 M |
-$183.42 M |
-$43.56 M |
| EBITDA Ratio |
-1.34
|
-1.97
|
-60.78
|
-5.12
|
-7.66
|
-56.66
|
-6.88
|
0
|
0
|
| Operating Income Ratio |
-1.13
|
-2.67
|
-65.29
|
-6.6
|
-8.27
|
-57.52
|
-6.56
|
0
|
0
|
| Total Other Income/Expenses Net |
-$165.90 M
|
$50.78 M
|
-$45.88 M
|
$27.55 M
|
-$9.82 M
|
-$31.01 M
|
-$22.35 M
|
$14.21 M
|
$26.00 K
|
| Income Before Tax |
-$734.99 M
|
-$542.19 M
|
-$653.25 M
|
-$484.65 M
|
-$586.45 M
|
-$505.49 M
|
-$288.59 M
|
-$169.45 M
|
-$43.83 M
|
| Income Before Tax Ratio |
-1.46
|
-2.44
|
-70.22
|
-6.24
|
-8.41
|
-61.28
|
-7.12
|
0
|
0
|
| Income Tax Expense |
$555.00 K
|
$1.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$729.31 M
|
-$535.76 M
|
-$643.20 M
|
-$481.18 M
|
-$562.54 M
|
-$448.72 M
|
-$260.44 M
|
-$130.75 M
|
-$30.57 M
|
| Net Income Ratio |
-1.45
|
-2.41
|
-69.14
|
-6.2
|
-8.07
|
-54.4
|
-6.42
|
0
|
0
|
| EPS |
-3.79 |
-2.88 |
-3.95 |
-3.35 |
-3.9 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| EPS Diluted |
-3.79 |
-2.88 |
-3.95 |
-3.35 |
-3.9 |
-4.1 |
-2.48 |
-1.42 |
-0.33 |
| Weighted Average Shares Out |
$197.24 M
|
$186.08 M
|
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Weighted Average Shares Out Diluted |
$197.24 M
|
$186.08 M
|
$162.79 M
|
$147.47 M
|
$144.36 M
|
$118.00 M
|
$105.10 M
|
$92.33 M
|
$92.33 M
|
| Link |
|
|
|
|
|
|
|
|
|
